Literature DB >> 16476273

[Acneiform eruption from epidermal growth factor receptor inhibitors].

Zuriñe Martínez de Lagrán1, Juan A Ratón, Olatz Lasa, Elvira Acebo, José L Díaz-Pérez.   

Abstract

One of the fundamental aims of oncological research is the search for molecules with greater efficacy against tumors and less toxicity than the usual chemotherapeutic agents. Epidermal growth factor receptor inhibitors are a new group of drugs which, because of their more specific effect against neoplastic cells, seem to meet these characteristics. Skin eruptions are one of the most frequent adverse effects associated with their use, secondary to the drug's direct inhibitory effect on homeostasis of the epidermis and of the pilosebaceous follicle. Several cases of cutaneous toxicity in patients treated with epidermal growth factor receptor inhibitors have recently been published. We present three cases of acneiform eruptions attributable to different drugs in this family (cetuximab, gefitinib and erlotinib).

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16476273     DOI: 10.1016/s0001-7310(05)73110-0

Source DB:  PubMed          Journal:  Actas Dermosifiliogr        ISSN: 0001-7310


  2 in total

1.  Detecting Chemotherapeutic Skin Adverse Reactions in Social Health Networks Using Deep Learning.

Authors:  Julia D Ransohoff; Azadeh Nikfarjam; Erik Jones; Brian Loew; Bernice Y Kwong; Kavita Y Sarin; Nigam H Shah
Journal:  JAMA Oncol       Date:  2018-04-01       Impact factor: 31.777

2.  Early Detection of Adverse Drug Reactions in Social Health Networks: A Natural Language Processing Pipeline for Signal Detection.

Authors:  Azadeh Nikfarjam; Julia D Ransohoff; Alison Callahan; Erik Jones; Brian Loew; Bernice Y Kwong; Kavita Y Sarin; Nigam H Shah
Journal:  JMIR Public Health Surveill       Date:  2019-06-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.